---
title: "Wedbush Keeps Their Buy Rating on PepGen Inc. (PEPG)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286263022.md"
description: "Wedbush analyst Laura Chico has maintained a Buy rating on PepGen Inc. (PEPG) with a price target of $4.00. Chico, a 5-star analyst, has an average return of 13.2% and a success rate of 52.03%. The analyst consensus for PepGen Inc. is Moderate Buy, with a price target consensus of $10.17."
datetime: "2026-05-13T12:37:33.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286263022.md)
  - [en](https://longbridge.com/en/news/286263022.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286263022.md)
---

# Wedbush Keeps Their Buy Rating on PepGen Inc. (PEPG)

Wedbush analyst Laura Chico maintained a Buy rating on PepGen Inc. today and set a price target of $4.00.

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

According to TipRanks, Chico is a 5-star analyst with an average return of 13.2% and a 52.03% success rate. Chico covers the Healthcare sector, focusing on stocks such as Viridian Therapeutics, Ovid Therapeutics, and Maze Therapeutics, Inc..

PepGen Inc. has an analyst consensus of Moderate Buy, with a price target consensus of $10.17.

### Related Stocks

- [PEPG.US](https://longbridge.com/en/quote/PEPG.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [XLV.US](https://longbridge.com/en/quote/XLV.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md)
- [VHT.US](https://longbridge.com/en/quote/VHT.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [VRDN.US](https://longbridge.com/en/quote/VRDN.US.md)
- [OVID.US](https://longbridge.com/en/quote/OVID.US.md)
- [MAZE.US](https://longbridge.com/en/quote/MAZE.US.md)

## Related News & Research

- [Roth MKM Sticks to Their Buy Rating for Capricor Therapeutics (CAPR)](https://longbridge.com/en/news/286497683.md)
- [Acrivon Therapeutics, Inc. (ACRV) Receives a Buy from Oppenheimer](https://longbridge.com/en/news/286428001.md)
- [Leerink Partners Sticks to Their Buy Rating for Ibio (IBIO)](https://longbridge.com/en/news/286588262.md)
- [MiNK Therapeutics' Q1 net loss narrows slightly](https://longbridge.com/en/news/286558132.md)
- [BUZZ-Street View: Regeneron's melanoma trial setback raises bigger-picture questions](https://longbridge.com/en/news/286769076.md)